NCT04887298View on ClinicalTrials.gov

Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 5, 2021

Primary Completion Date

September 29, 2022

Study Completion Date

August 6, 2024

Conditions
Sarcoma,Soft TissuePulmonary Metastasis
Interventions
DRUG

Liposomal Annamycin (L-Annamycin)

2-hour intravenous (IV) infusion of L-Annamycin on Day 1 followed by 20 days off of study drug (i.e., 1 treatment cycle= 21 days)

Trial Locations (5)

43210

Ohio State University, Columbus

63110

Washington University, St Louis

77030

The University of Texas MD Anderson Cancer Center, Houston

90403

Sarcoma Oncology Center, Santa Monica

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

Sponsors
All Listed Sponsors
lead

Moleculin Biotech, Inc.

INDUSTRY

NCT04887298 - Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases | Biotech Hunter | Biotech Hunter